A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia
NCT ID: NCT02192723
Last Updated: 2016-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
550 participants
INTERVENTIONAL
2012-06-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients
NCT00645372
Validating and Optimizing Model of Antipsychotics Selection
NCT03237052
An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia
NCT02640911
Antipsychotic to Treat Psychosis Syndrome
NCT02137616
Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia
NCT02137993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
METHODS: A total of 550 patients with schizophrenia were recruited at 4 Chinese sites and randomly assigned to receive perphenazine (16 to 64 mg per day) or haloperidol(6 t0 20mg per day), olanzapine (5 to 20 mg per day), quetiapine (400 to 750 mg per day), aripiprazole (10 to 30 mg per day) or risperidone (2 to 6.0 mg per day) for up to 8 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Typical antipsychotic
Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day) for 8 weeks.
Typical antipsychotic
Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
Risperidone
Risperidone, 2\~6mg/day, twice day, 8 weeks
Risperidone
2\~6mg/day, twice per day, 8 weeks
Olanzapine
5\~20mg/day
Olanzapine
Olanzapine, 400\~750mg/day, twice per day, 8 weeks
Quetiapine
400\~750mg/day
Quetiapine
Quetiapine, 400～750mg/day, twice per day, 8 weeks
Aripiprazole
Aripiprazole, 10\~30mg/day, twice per day, 8 weeks
Aripiprazole
Aripiprazole, 10～30mg/day, twice per day, 8 weeks
Ziprasidone
Ziprasidone, 80\~160mg/day, twice per day, 8 weeks
Ziprasidone
Ziprasidone 80\~160mg/day, twice per day, 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Typical antipsychotic
Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
Risperidone
2\~6mg/day, twice per day, 8 weeks
Olanzapine
Olanzapine, 400\~750mg/day, twice per day, 8 weeks
Quetiapine
Quetiapine, 400～750mg/day, twice per day, 8 weeks
Aripiprazole
Aripiprazole, 10～30mg/day, twice per day, 8 weeks
Ziprasidone
Ziprasidone 80\~160mg/day, twice per day, 8 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must meet the following criteria: (1) diagnosis of schizophrenia; (2) duration of illness more than 2 years; (3) between 25 and 60 years of age; and (5) have NOT received antipsychotic medication for at least 1 month;(6) acute exacerbations of chronic inpatients.
* A complete medical history, electroencephalograms and electrocardiogram are obtained, and a physical examination and laboratory tests are performed at study entrance. None of the study participants have abnormal findings on these tests.
Exclusion Criteria
25 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing HuiLongGuan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiang Yang Zhang
Director, the Research Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhi-Ren Wang, MD, PhD
Role: STUDY_DIRECTOR
Beijing HuiLongGuan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing HuiLongGuan Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Project863
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.